The world's first and only Anyfusion to receive FDA STeP designation.

The safety and efficacy of Anyfusion was verified and the ICU of S Hospital, a cardiac specialist in Bucheon, decided to purchase the Anyfusion Cylinder pump.

Incheon and Bucheon S hospitals are the best heart hospitals in Korea. We upgraded some deficiencies pointed out in the first demo of Anyfusion and conducted a second demo, and the safety and effectiveness were verified, so S Hospital decided to purchase and delivered it.

Before introducing Anyfusion, the hospital was conducting a comparative demo of existing domestic and overseas products due to the increase in patients due to the medical crisis. The medical engineering and administrative departments of the hospital strongly recommended overseas products (Japan) due to the low reliability of domestic products.

Anyfusion was the last to be demoed and had some problems, but it gave us the opportunity to upgrade, and it did not have favorable competitive factors such as the administration's negative opinion of domestic products, high consumable prices, and lack of long-term reliability evidence for hundreds, thousands, or tens of thousands of units, but it solved the workload with the most important human error prevention program, FDA STeP, etc. Clinical safety and real-time quantitative, accurate, and precise infusion validity were evaluated by practitioners as "favorite pumps" including global major Japanese products as confirmation of use.

Long-term reliability for decades is important, but safety and effectiveness, which is impossible for existing products, are the top priority. It is important to note that the elements that were selected over global major products because they reduce human errors and work of medical staff, are effective in treating diseases (patients), and were selected by STeP as the safest infusion pump designated as an innovative medical device by the FDA were verified and confirmed in this demo. It is an urgently needed device for patients and medical staff in the U.S. and developed markets, where the world is the same and especially eye-care is emphasized. It is a source technology that will be highly valued in the US stock market 

So far, Anyfusion has been used primarily in NICUs, where a single patient uses only one or two pumps, and the supplies are not used for more than a day due to their susceptibility to ocular infections. There were no references from ICUs, the main market for the pump, where a single patient uses an average of 5-6 pumps, with more than 10 pumps depending on the severity of the disease.

Although there were some insufficient conditions in the intensive care unit (ICU) of Hospital S, where 70~80% of patients use syringe pumps and the ICU is at the level of a university hospital, the reference that was finally decided to be used due to the perfect safety and efficacy competitiveness selected by the FDA as STeP in the first real world of ICU will be an important factor to be resilient to other hospitals in Korea and global market expansion.

The ICU of Hospital S uses a method of filling syringes with drugs and solutions according to the degree of illness of patients who cannot use conventional pumps, adjusting the concentration (during which the concentration is calculated manually (human error factor), and Anyfusion has an automatic calculation program), and filling them into large containers (bottles or bags), Injecting medicines and nutrients in the prescribed dosage required to treat the disease with real-time accuracy, without frequent container replacement like syringes for 3-4 days, improving clinical treatment effectiveness and reducing workload caused by frequent replacement, and preventing infections and human error, because it is the first in the world to confirm and verify safety.

The paradigm of infusion pumps has changed to Anyfusion, which is bound to be a game changer. Once these facts are confirmed by the medical staff, no hospital or country will not replace it. This is the reason why Hospital S decided early, and it is bound to expand to other hospitals and countries.

We will do our best to aim for 0% defect rate with real-time prompt after-sales service (A/S) and the highest quality production management for globalization based on the real world reference of large quantities of Anyfusion pump for many years.

Korea's core original technology product will be the first global leader product. With Anyfusion ACPi Pro of cylinder cartridge technology...

Thank you.